(untitled) - Jankovic, J; Goodman, I; Safirstein, B; Schenk, D; Kinney, G G; Koller, M; Ness, D K; Griffith, S G; Grundman, M; Soto, J; Ostrowitzki, S; Boess, F G; Martin-Facklam, M G; Quinn, J F; Isaacson, S H; Jennings, D; Omidvar, O; Ellenbogen, A
Results from a phase 1b multiple ascending-dose study of PRX002, an anti–alpha-synuclein monoclonal antibody, in patients with Parkinson's disease. Presented at the 13th International Conference on Alzheimer's and Parkinson's Disease, Vienna, Austria, 4/2/2017